Request Free Sample ×
Thyroid Disorder Market Research Report - Forecast till 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Thyroid Disorder Market

ID: MRFR/Pharma/2031-CR
118 Pages
Satyendra Maurya
Last Updated: January 13, 2026

甲状腺疾患市場調査レポートのタイプ別（甲状腺機能低下症および甲状腺機能亢進症）、治療法（薬物療法、放射性ヨウ素療法、手術）、投与経路（経口、静脈内など）、エンドユーザー（病院、診療所など）および地域（アメリカ、ヨーロッパ、アジア太平洋、中東およびアフリカ）ごとの情報 - 2032年までの予測

共有
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Thyroid Disorder Market Infographic
Purchase Options
Compare License
概要 目次 セグメンテーション PDFをダウンロード
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Thyroid Disorder Type Outlook (USD Billion)
  49.     4.1.1 Hypothyroidism
  50.     4.1.2 Hyperthyroidism
  51.   4.2 Healthcare, BY Thyroid Disorder Treatment Outlook (USD Billion)
  52.     4.2.1 Medications
  53.     4.2.2 Surgery
  54.     4.2.3 Radioactive iodine therapy
  55.   4.3 Healthcare, BY Thyroid Disorder Route of Administration Outlook (USD Billion)
  56.     4.3.1 Intravenous
  57.     4.3.2 Oral
  58.     4.3.3 Other
  59.   4.4 Healthcare, BY Thyroid Disorder End-User Outlook (USD Billion)
  60.     4.4.1 Clinics
  61.     4.4.2 Hospitals
  62.     4.4.3 Others
  63.   4.5 Healthcare, BY Region (USD Billion)
  64.     4.5.1 North America
  65.       4.5.1.1 US
  66.       4.5.1.2 Canada
  67.     4.5.2 Europe
  68.       4.5.2.1 Germany
  69.       4.5.2.2 UK
  70.       4.5.2.3 France
  71.       4.5.2.4 Russia
  72.       4.5.2.5 Italy
  73.       4.5.2.6 Spain
  74.       4.5.2.7 Rest of Europe
  75.     4.5.3 APAC
  76.       4.5.3.1 China
  77.       4.5.3.2 India
  78.       4.5.3.3 Japan
  79.       4.5.3.4 South Korea
  80.       4.5.3.5 Malaysia
  81.       4.5.3.6 Thailand
  82.       4.5.3.7 Indonesia
  83.       4.5.3.8 Rest of APAC
  84.     4.5.4 South America
  85.       4.5.4.1 Brazil
  86.       4.5.4.2 Mexico
  87.       4.5.4.3 Argentina
  88.       4.5.4.4 Rest of South America
  89.     4.5.5 MEA
  90.       4.5.5.1 GCC Countries
  91.       4.5.5.2 South Africa
  92.       4.5.5.3 Rest of MEA
  93. 5 SECTION V: COMPETITIVE ANALYSIS
  94.   5.1 Competitive Landscape
  95.     5.1.1 Overview
  96.     5.1.2 Competitive Analysis
  97.     5.1.3 Market share Analysis
  98.     5.1.4 Major Growth Strategy in the Healthcare
  99.     5.1.5 Competitive Benchmarking
  100.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  101.     5.1.7 Key developments and growth strategies
  102.       5.1.7.1 New Product Launch/Service Deployment
  103.       5.1.7.2 Merger & Acquisitions
  104.       5.1.7.3 Joint Ventures
  105.     5.1.8 Major Players Financial Matrix
  106.       5.1.8.1 Sales and Operating Income
  107.       5.1.8.2 Major Players R&D Expenditure. 2023
  108.   5.2 Company Profiles
  109.     5.2.1 AbbVie (US)
  110.       5.2.1.1 Financial Overview
  111.       5.2.1.2 Products Offered
  112.       5.2.1.3 Key Developments
  113.       5.2.1.4 SWOT Analysis
  114.       5.2.1.5 Key Strategies
  115.     5.2.2 Bristol-Myers Squibb (US)
  116.       5.2.2.1 Financial Overview
  117.       5.2.2.2 Products Offered
  118.       5.2.2.3 Key Developments
  119.       5.2.2.4 SWOT Analysis
  120.       5.2.2.5 Key Strategies
  121.     5.2.3 Eli Lilly and Company (US)
  122.       5.2.3.1 Financial Overview
  123.       5.2.3.2 Products Offered
  124.       5.2.3.3 Key Developments
  125.       5.2.3.4 SWOT Analysis
  126.       5.2.3.5 Key Strategies
  127.     5.2.4 Merck & Co. (US)
  128.       5.2.4.1 Financial Overview
  129.       5.2.4.2 Products Offered
  130.       5.2.4.3 Key Developments
  131.       5.2.4.4 SWOT Analysis
  132.       5.2.4.5 Key Strategies
  133.     5.2.5 Novartis (CH)
  134.       5.2.5.1 Financial Overview
  135.       5.2.5.2 Products Offered
  136.       5.2.5.3 Key Developments
  137.       5.2.5.4 SWOT Analysis
  138.       5.2.5.5 Key Strategies
  139.     5.2.6 Pfizer (US)
  140.       5.2.6.1 Financial Overview
  141.       5.2.6.2 Products Offered
  142.       5.2.6.3 Key Developments
  143.       5.2.6.4 SWOT Analysis
  144.       5.2.6.5 Key Strategies
  145.     5.2.7 Sanofi (FR)
  146.       5.2.7.1 Financial Overview
  147.       5.2.7.2 Products Offered
  148.       5.2.7.3 Key Developments
  149.       5.2.7.4 SWOT Analysis
  150.       5.2.7.5 Key Strategies
  151.     5.2.8 Takeda Pharmaceutical Company (JP)
  152.       5.2.8.1 Financial Overview
  153.       5.2.8.2 Products Offered
  154.       5.2.8.3 Key Developments
  155.       5.2.8.4 SWOT Analysis
  156.       5.2.8.5 Key Strategies
  157.     5.2.9 Amgen (US)
  158.       5.2.9.1 Financial Overview
  159.       5.2.9.2 Products Offered
  160.       5.2.9.3 Key Developments
  161.       5.2.9.4 SWOT Analysis
  162.       5.2.9.5 Key Strategies
  163.   5.3 Appendix
  164.     5.3.1 References
  165.     5.3.2 Related Reports
  166. 6 LIST OF FIGURES
  167.   6.1 MARKET SYNOPSIS
  168.   6.2 NORTH AMERICA MARKET ANALYSIS
  169.   6.3 US MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  170.   6.4 US MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  171.   6.5 US MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  172.   6.6 US MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  173.   6.7 CANADA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  174.   6.8 CANADA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  175.   6.9 CANADA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  176.   6.10 CANADA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  177.   6.11 EUROPE MARKET ANALYSIS
  178.   6.12 GERMANY MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  179.   6.13 GERMANY MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  180.   6.14 GERMANY MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  181.   6.15 GERMANY MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  182.   6.16 UK MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  183.   6.17 UK MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  184.   6.18 UK MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  185.   6.19 UK MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  186.   6.20 FRANCE MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  187.   6.21 FRANCE MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  188.   6.22 FRANCE MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  189.   6.23 FRANCE MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  190.   6.24 RUSSIA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  191.   6.25 RUSSIA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  192.   6.26 RUSSIA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  193.   6.27 RUSSIA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  194.   6.28 ITALY MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  195.   6.29 ITALY MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  196.   6.30 ITALY MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  197.   6.31 ITALY MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  198.   6.32 SPAIN MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  199.   6.33 SPAIN MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  200.   6.34 SPAIN MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  201.   6.35 SPAIN MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  202.   6.36 REST OF EUROPE MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  203.   6.37 REST OF EUROPE MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  204.   6.38 REST OF EUROPE MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  205.   6.39 REST OF EUROPE MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  206.   6.40 APAC MARKET ANALYSIS
  207.   6.41 CHINA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  208.   6.42 CHINA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  209.   6.43 CHINA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  210.   6.44 CHINA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  211.   6.45 INDIA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  212.   6.46 INDIA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  213.   6.47 INDIA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  214.   6.48 INDIA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  215.   6.49 JAPAN MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  216.   6.50 JAPAN MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  217.   6.51 JAPAN MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  218.   6.52 JAPAN MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  219.   6.53 SOUTH KOREA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  220.   6.54 SOUTH KOREA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  221.   6.55 SOUTH KOREA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  222.   6.56 SOUTH KOREA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  223.   6.57 MALAYSIA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  224.   6.58 MALAYSIA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  225.   6.59 MALAYSIA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  226.   6.60 MALAYSIA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  227.   6.61 THAILAND MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  228.   6.62 THAILAND MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  229.   6.63 THAILAND MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  230.   6.64 THAILAND MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  231.   6.65 INDONESIA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  232.   6.66 INDONESIA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  233.   6.67 INDONESIA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  234.   6.68 INDONESIA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  235.   6.69 REST OF APAC MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  236.   6.70 REST OF APAC MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  237.   6.71 REST OF APAC MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  238.   6.72 REST OF APAC MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  239.   6.73 SOUTH AMERICA MARKET ANALYSIS
  240.   6.74 BRAZIL MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  241.   6.75 BRAZIL MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  242.   6.76 BRAZIL MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  243.   6.77 BRAZIL MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  244.   6.78 MEXICO MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  245.   6.79 MEXICO MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  246.   6.80 MEXICO MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  247.   6.81 MEXICO MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  248.   6.82 ARGENTINA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  249.   6.83 ARGENTINA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  250.   6.84 ARGENTINA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  251.   6.85 ARGENTINA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  252.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  253.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  254.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  255.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  256.   6.90 MEA MARKET ANALYSIS
  257.   6.91 GCC COUNTRIES MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  258.   6.92 GCC COUNTRIES MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  259.   6.93 GCC COUNTRIES MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  260.   6.94 GCC COUNTRIES MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  261.   6.95 SOUTH AFRICA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  262.   6.96 SOUTH AFRICA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  263.   6.97 SOUTH AFRICA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  264.   6.98 SOUTH AFRICA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  265.   6.99 REST OF MEA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
  266.   6.100 REST OF MEA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
  267.   6.101 REST OF MEA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
  268.   6.102 REST OF MEA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
  269.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  270.   6.104 RESEARCH PROCESS OF MRFR
  271.   6.105 DRO ANALYSIS OF HEALTHCARE
  272.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  273.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  274.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  275.   6.109 HEALTHCARE, BY THYROID DISORDER TYPE OUTLOOK, 2024 (% SHARE)
  276.   6.110 HEALTHCARE, BY THYROID DISORDER TYPE OUTLOOK, 2024 TO 2035 (USD Billion)
  277.   6.111 HEALTHCARE, BY THYROID DISORDER TREATMENT OUTLOOK, 2024 (% SHARE)
  278.   6.112 HEALTHCARE, BY THYROID DISORDER TREATMENT OUTLOOK, 2024 TO 2035 (USD Billion)
  279.   6.113 HEALTHCARE, BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2024 (% SHARE)
  280.   6.114 HEALTHCARE, BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2024 TO 2035 (USD Billion)
  281.   6.115 HEALTHCARE, BY THYROID DISORDER END-USER OUTLOOK, 2024 (% SHARE)
  282.   6.116 HEALTHCARE, BY THYROID DISORDER END-USER OUTLOOK, 2024 TO 2035 (USD Billion)
  283.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  284. 7 LIST OF TABLES
  285.   7.1 LIST OF ASSUMPTIONS
  286.     7.1.1
  287.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  288.     7.2.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  289.     7.2.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  290.     7.2.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  291.     7.2.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  292.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  293.     7.3.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  294.     7.3.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  295.     7.3.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  296.     7.3.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  297.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  298.     7.4.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  299.     7.4.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  300.     7.4.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  301.     7.4.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  302.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  303.     7.5.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  304.     7.5.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  305.     7.5.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  306.     7.5.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  307.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  308.     7.6.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  309.     7.6.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  310.     7.6.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  311.     7.6.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  312.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  313.     7.7.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  314.     7.7.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  315.     7.7.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  316.     7.7.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  317.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  318.     7.8.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  319.     7.8.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  320.     7.8.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  321.     7.8.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  322.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  323.     7.9.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  324.     7.9.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  325.     7.9.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  326.     7.9.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  327.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  328.     7.10.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  329.     7.10.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  330.     7.10.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  331.     7.10.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  332.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  333.     7.11.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  334.     7.11.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  335.     7.11.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  336.     7.11.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  337.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  338.     7.12.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  339.     7.12.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  340.     7.12.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  341.     7.12.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  342.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  343.     7.13.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  344.     7.13.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  345.     7.13.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  346.     7.13.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  347.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  348.     7.14.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  349.     7.14.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  350.     7.14.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  351.     7.14.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  352.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  353.     7.15.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  354.     7.15.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  355.     7.15.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  356.     7.15.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  357.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  358.     7.16.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  359.     7.16.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  360.     7.16.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  361.     7.16.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  362.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  363.     7.17.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  364.     7.17.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  365.     7.17.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  366.     7.17.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  367.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  368.     7.18.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  369.     7.18.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  370.     7.18.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  371.     7.18.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  372.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  373.     7.19.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  374.     7.19.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  375.     7.19.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  376.     7.19.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  377.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  378.     7.20.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  379.     7.20.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  380.     7.20.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  381.     7.20.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  382.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  383.     7.21.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  384.     7.21.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  385.     7.21.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  386.     7.21.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  387.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  388.     7.22.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  389.     7.22.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  390.     7.22.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  391.     7.22.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  392.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  393.     7.23.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  394.     7.23.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  395.     7.23.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  396.     7.23.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  397.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  398.     7.24.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  399.     7.24.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  400.     7.24.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  401.     7.24.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  402.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  403.     7.25.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  404.     7.25.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  405.     7.25.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  406.     7.25.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  407.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  408.     7.26.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  409.     7.26.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  410.     7.26.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  411.     7.26.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  412.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  413.     7.27.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  414.     7.27.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  415.     7.27.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  416.     7.27.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  417.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  418.     7.28.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  419.     7.28.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  420.     7.28.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  421.     7.28.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  422.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  423.     7.29.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  424.     7.29.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  425.     7.29.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  426.     7.29.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  427.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  428.     7.30.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
  429.     7.30.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
  430.     7.30.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
  431.     7.30.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
  432.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  433.     7.31.1
  434.   7.32 ACQUISITION/PARTNERSHIP
  435.     7.32.1

関連レポート

この市場に関する地域レポートはありません。

この市場に関する国別レポートはありません。

Customer Stories
Case Study Cover Image
ケーススタディ

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓